deltatrials
Unknown OBSERVATIONAL NCT03713931

PUMA Implementation 2 (IPUMA2)

BUSQUEDA ACTIVA DE CASOS DE EPOC EN EL PRIMER NIVEL DE ATENCION: USO DEL SCORE PUMA PARA TAMIZAJE DE EPOC

Sponsor: AstraZeneca

Conditions Adult COPD Diagnosis Primary Care Risk Factors Screening Score Spirometry
Interventions PUMA Score questionnaire
Updated 5 times since 2018 Last updated: Dec 26, 2018 Started: Nov 14, 2018 Primary completion: Dec 21, 2018 Completion: Jan 21, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Adult and COPD and is currently ongoing. AstraZeneca leads this study, which shows 5 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshotNot Yet Recruiting~Jan 2019 – ~Jan 2021 · 24 months · monthly snapshotRecruiting~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status

    Status: Recruiting → Unknown Status

  4. Jan 2019 — Jan 2021 [monthly]

    Recruiting

    Status: Not Yet Recruiting → Recruiting

  5. Nov 2018 — Jan 2019 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Gustavo Zabert, MD
Data source: Asociacion Latinoamericana de Torax

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations